BNP Paribas Financial Markets
STRO icon

BNP Paribas Financial Markets’s Sutro Biopharma STRO Stock Holding History

BNP Paribas Financial Markets’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.77K Hold
111
– – ﹤0.01% 5385
2025
Q4 		$1.28K Sell
111
-63
-36% -$598 ﹤0.01% 5382
2025
Q3 		$1.51K Sell
174
-66
-28% -$562 ﹤0.01% 5193
2025
Q2 		$1.71K Sell
240
-15,284
-98% -$125K ﹤0.01% 5081
2025
Q1 		$101K Buy
15,524
+448
+3% +$7.06K ﹤0.01% 4037
2024
Q4 		$277K Buy
15,076
+6,824
+83% +$208K ﹤0.01% 3685
2024
Q3 		$286K Buy
8,252
+7,615
+1,195% +$298K ﹤0.01% 3103
2024
Q2 		$18.7K Sell
637
-9,186
-94% -$363K ﹤0.01% 3651
2024
Q1 		$555K Buy
9,823
+8,186
+500% +$362K ﹤0.01% 2784
2023
Q4 		$70.2K Sell
1,637
-1,673
-51% -$53.1K ﹤0.01% 3493
2023
Q3 		$115K Buy
3,310
+648
+24% +$28.2K ﹤0.01% 3290
2023
Q2 		$124K Sell
2,662
-7,773
-74% -$387K ﹤0.01% 3193
2023
Q1 		$482K Buy
10,435
+7,219
+224% +$458K ﹤0.01% 2758
2022
Q4 		$260K Sell
3,216
-799
-20% -$55.5K ﹤0.01% 2901
2022
Q3 		$223K Buy
4,015
+619
+18% +$36.6K ﹤0.01% 3447
2022
Q2 		$177K Buy
3,396
+748
+28% +$41.8K ﹤0.01% 3142
2022
Q1 		$218K Buy
2,648
+947
+56% +$90.1K ﹤0.01% 3093
2021
Q4 		$253K Buy
1,701
+650
+62% +$116K ﹤0.01% 3298
2021
Q3 		$199K Buy
1,051
+600
+133% +$114K ﹤0.01% 3042
2021
Q2 		$83.9K Sell
451
-2,354
-84% -$461K ﹤0.01% 3091
2021
Q1 		$639K Buy
2,805
+2,191
+357% +$520K ﹤0.01% 2427
2020
Q4 		$133K Sell
614
-5
-0.8% -$828 ﹤0.01% 3078
2020
Q3 		$62.2K Buy
619
+536
+646% +$50.6K ﹤0.01% 3368
2020
Q2 		$6.43K Sell
83
-255
-75% -$24.5K ﹤0.01% 3895
2020
Q1 		$34.5K Buy
338
+95
+39% +$9.98K ﹤0.01% 3721
2019
Q4 		$26.7K Buy
243
+116
+91% +$12K ﹤0.01% 3921
2019
Q3 		$11.6K Buy
127
+9
+8% +$909 ﹤0.01% 4124
2019
Q2 		$13.4K Sell
118
-34
-22% -$3.75K ﹤0.01% 4035
2019
Q1 		$17.3K Buy
+152
New +$15.8K ﹤0.01% 3935

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BNP Paribas Financial Markets's STRO Position: Q1 2026 in Review

BNP Paribas Financial Markets held its Sutro Biopharma (STRO) position steady in Q1 2026 at 111 shares worth $2.77K. The position accounts for ﹤0.01% of the portfolio, ranked #5385.

BNP Paribas Financial Markets first reported a position in STRO in Q1 2019 and has held it in 29 quarters since. The position peaked at $639K in Q1 2021. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • BNP Paribas Financial Markets held 111 shares of Sutro Biopharma worth $2.77K as of Q1 2026.
  • BNP Paribas Financial Markets left its Sutro Biopharma share count unchanged in Q1 2026.
  • Sutro Biopharma made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5385 holding.
  • BNP Paribas Financial Markets first reported a position in Sutro Biopharma in Q1 2019 and has held it in 29 quarters since.
  • BNP Paribas Financial Markets's Sutro Biopharma position peaked at $639K in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.